Company news
Oncolytics Biotech Inc. news in 2019
Oncolytics Biotech Inc.'s news releases, calls and decks from 2019, newest first.
Oncolytics Biotech(R) Announces Abstract Outlining Potential New Biomarker to be Presented at the 2020 Gastrointestinal Cancers Symposium
December 12, 2019
Oncolytics Biotech(R) Announces Positive Multiple Myeloma Data Presented at the 61st Annual Meeting & Exposition of the American Society of Hematology
December 9, 2019
Oncolytics Biotech(R) Regains Compliance with Nasdaq Minimum Bid Price Requirement
December 6, 2019
Oncolytics Biotech(R) Presents Clinical Data at the Fifth Annual Oncolytic Virotherapy Conference Highlighting Definitive Evidence of Systemic Delivery and Replication of Pelareorep in Tumor Tissue
December 3, 2019
Oncolytics Biotech(R) Reports 2019 Third Quarter Financial Results and Operational Highlights
November 12, 2019
Oncolytics Biotech(R) Announces Exercise of Warrants
November 12, 2019
Oncolytics Biotech(R) Announces AWARE-1 Data Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer
November 8, 2019
Oncolytics Biotech(R) Announces Abstract Published for the 61st Annual Meeting & Exposition of the American Society of Hematology
November 6, 2019
Oncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma
November 6, 2019
Oncolytics Biotech(R) Provides Update on Partner Adlai Nortye's Clinical Progress
October 31, 2019
Oncolytics Biotech(R) and PrECOG Announce Collaboration for BRACELET-1 (PrE0113) Study in Metastatic Breast Cancer
October 22, 2019
Oncolytics Biotech(R) Appoints Experienced Financial and Strategic Leader Leonard Kruimer to Board of Directors
October 17, 2019
Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors
October 15, 2019
Oncolytics Biotech(R) Announces Abstract to be Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer
October 1, 2019
Oncolytics Biotech CEO, Matt Coffey, Honored with Scientific Achievement and Innovation Award by BioAlberta
September 30, 2019
Oncolytics Biotech(R) Announces Upcoming Presentation at the 12th Annual International Oncolytics Virus Conference
September 25, 2019
Oncolytics Biotech(R) Announces Upcoming Conference Participation
September 23, 2019
Oncolytics Biotech(R) Receives Nasdaq Notification Letter
September 20, 2019
Oncolytics Biotech(R) to Present at the Ladenburg Thalmann Healthcare Conference
September 17, 2019
Oncolytics Biotech(R) to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 5, 2019
Oncolytics Biotech(R) to Host Corporate Update Call to Discuss Recent Highlights and Expanded Catalysts and Milestones
September 4, 2019
Oncolytics Biotech(R) Announces Closing of Its Public Offering of Common Shares and Warrants
August 16, 2019
CORRECTION: Oncolytics Biotech(R) Announces Pricing of Its USD $3.7M - CDN $4.9M Public Offering of Common Share and Warrants
August 14, 2019
Oncolytics Biotech(R) Announces Pricing of Its Public Offering of Common Share and Warrants
August 14, 2019
Oncolytics Biotech(R) Announces Preliminary AWARE-1 Trial Data Demonstrating Viral Replication and Promotion of Inflammation Following Systemic Administration of Pelareorep When Combined with Tecentriq(R)
July 23, 2019
Oncolytics Biotech (R) to Host Conference Call to Discuss Co-Development Agreement with Pfizer and Merck KGaA
June 5, 2019
Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer
June 5, 2019
Oncolytics Biotech(R) to Present at the 9th Annual LD Micro Invitational Investor Conference
May 29, 2019
Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual Meeting
May 16, 2019
Oncolytics Biotech (R) Reports 2019 First Quarter Financial Results and Operational Highlights
May 3, 2019
Oncolytics Biotech(R) Announces Voting Results from the Annual General Meeting of Shareholders
May 3, 2019
Oncolytics Biotech(R) to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
April 23, 2019
Oncolytics Biotech(R) Announces First Patient Treated in Company's AWARE-1 Window of Opportunity Study of Pelareorep in Breast Cancer
April 8, 2019
Oncolytics Biotech(R) to Host Key Opinion Leader Meeting on the Emerging Role of Biomarkers and Oncolytic Viruses in the Treatment of Cancer
April 4, 2019
Oncolytics Biotech(R) to Present at the 18th Annual Needham Healthcare Conference
April 3, 2019
Oncolytics Biotech (R) Presents Positive Clinical Biomarker Data at the American Association for Cancer Research Annual Meeting 2019
April 2, 2019
Oncolytics Biotech (R) Announces a Publication Highlighting Synergistic Effect of Pelareorep with a Proteasome Inhibitor in Preclinical Models of Multiple Myeloma
March 28, 2019
Oncolytics Biotech (R) Announces 2018 Year-End Results and Operational Highlights
March 8, 2019
Oncolytics Biotech(R) to Host Conference Call to Discuss Year End Financial Results and Operational Highlights
March 1, 2019
Oncolytics Biotech(R) Presents Biomarker Data in Second-line Pancreatic Cancer at AACR
February 27, 2019
Oncolytics Biotech(R) Announces Spanish Regulatory Approval of AWARE-1 Window of Opportunity Study in Breast Cancer
February 11, 2019
Oncolytics Biotech(R) to Present at the 21st Annual BIO CEO & Investor Conference
February 4, 2019